FDA Lifts Hold on Novavax's COVID-19 and Flu Vaccine Trials

The U.S. FDA has lifted the clinical hold on Novavax's COVID-19-Influenza Combination and stand-alone influenza vaccine candidates, allowing the company to proceed with a Phase 3 trial. This decision follows Novavax's successful response to concerns about a serious adverse event reported in a Phase 2 trial, which was determined not to be related to the vaccine. Novavax plans to begin the trial promptly, continuing its work on innovative vaccines to combat infectious diseases.